Evidence map›Paper›PMID 33133796›Full record

ArticleCureus2020

Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases.

Ouissam Al Jarroudi, Ayhan Ulusakarya, Wathek Almohamad, Said Afqir, Jean-Francois Morere

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Guideline
  2. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis.Liver international : official journal of the International Association for the Study of the Liver · 2023
    Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Ouissam Al JarroudiMedical Oncology, University Hospital Mohammed VI, Oujda, MAR.
Ayhan UlusakaryaMedical Oncology, Assistance Publique - Hôpitaux de Paris (AP-HP) Paul Brousse Hospital, Paris, FRA.
Wathek AlmohamadMedical Oncology, Assistance Publique - Hôpitaux de Paris (AP-HP) Paul Brousse Hospital, Paris, FRA.
Said AfqirMedical Oncology, University Hospital Mohammed VI, Oujda, MAR.
Jean-Francois MorereMedical Oncology, Assistance Publique - Hôpitaux de Paris (AP-HP) Paul Brousse Hospital, Paris, FRA.
Assistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire Mohammed VI · MAMohamed I University · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of recurrent hepatocellular carcinoma (HCC) after liver transplantation is difficult due to the lack of effective treatment options. The available evidence on the emerging immunotherapy in liver transplantation is based on anecdotal experiences and requires additional investigations. To determine the efficacy and safety of immunotherapy in liver transplant recipients, we report three cases of recurrent metastatic HCC after liver transplantation who were treated with nivolumab as off-label salvage therapy.

Indexed as

hepatocellular carcinomaliver transplantationpd-1 inhibitor

Identifiers

PMID33133796
PMCPMC7586420
OpenAlexW3094253006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.